Key result
CASES trial tests immediate versus delayed carotid stenting for acute stroke with tandem lesions.
Why the study?
Does immediate carotid artery stenting during endovascular treatment improve functional outcomes at 90 days in patients with acute ischemic stroke and tandem lesions compared to a deferred strategy?
RCT (n=600)
Open-label blinded endpoint
randomized
Yes
Does immediate carotid artery stenting during endovascular treatment improve functional outcomes at 90 days in patients with acute ischemic stroke and tandem lesions compared to a deferred strategy?
Answers are grounded in this paper and cite their sources.
The CASES trial protocol describes a phase 3 RCT to evaluate the efficacy and safety of immediate carotid artery stenting versus a deferred strategy in patients undergoing endovascular treatment for acute ischemic stroke with tandem lesions.
Background The optimal acute management of patients with acute ischemic stroke and a tandem lesion, defined as intracranial large vessel occlusion (LVO) with concomitant carotid artery stenosis or occlusion, remains unclear. Our aim is to assess the efficacy and safety of immediate carotid artery stenting (CAS) compared to delayed management in patients undergoing endovascular treatment (EVT) for acute ischemic stroke due to tandem lesions. Study design CASES is a phase 3 multicenter prospective randomized open-label blinded endpoint (PROBE) non-inferiority clinical trial. Patients with a computed tomography angiography proven intracranial LVO in the anterior circulation and ipsilateral proximal carotid artery stenosis (⩾50%) or occlusion of presumed atherosclerotic origin will be randomized to either immediate CAS during EVT or to EVT followed by a deferred strategy, which may include carotid endarterectomy (CEA), CAS, or medical management. CASES will be conducted in 27 EVT centers in Belgium and the Netherlands. A total of 600 patients will be included. Study outcomes The primary outcome is the score on the modified Rankin Scale (mRS) at 90 days. Secondary outcomes include excellent (mRS 0–1) and good (mRS 0–2) functional outcome at 90 days, stroke severity measured with the National Institutes of Health Stroke Scale (NIHSS) at 24 h and 5–7 days, recanalization, infarct volume at 24 h, ischemic stroke recurrence, carotid artery re-occlusion, symptomatic intracranial hemorrhage, and mortality. Summary This study will provide high-quality randomized data on the efficacy and safety of immediate CAS in patients undergoing EVT for acute ischemic stroke due to a tandem lesion. Trial registration ClinicalTrials.gov NCT06511089; ISRCTN 14956654
No takes yet. Share an insight, caveat, or question.
Maes et al. (2025) conducted an RCT in Acute ischemic stroke with tandem lesions (n=600). Immediate carotid artery stenting (CAS) during EVT vs. EVT followed by a deferred strategy (CEA, CAS, or medical management) was evaluated on Score on the modified Rankin Scale (mRS) at 90 days. The CASES trial is a phase 3 randomized protocol designed to evaluate if immediate carotid artery stenting is noninferior to delayed management for acute ischemic stroke with tandem lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: